Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785749

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785749

Atopic Dermatitis Clinical Trials

PUBLISHED:
PAGES: 216 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Atopic Dermatitis Clinical Trials Market to Reach US$5.0 Billion by 2030

The global market for Atopic Dermatitis Clinical Trials estimated at US$2.8 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 10.4% over the analysis period 2024-2030. Small Molecules, one of the segments analyzed in the report, is expected to record a 12.3% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Large Molecules segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$727.5 Million While China is Forecast to Grow at 9.4% CAGR

The Atopic Dermatitis Clinical Trials market in the U.S. is estimated at US$727.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$769.8 Million by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global Atopic Dermatitis Clinical Trials Market - Key Trends & Drivers Summarized

How Are Clinical Trials Advancing Atopic Dermatitis Treatments?

Atopic dermatitis, a chronic inflammatory skin condition, has prompted significant advancements in clinical trials aimed at identifying effective treatments. These trials focus on novel therapies, including biologics, JAK inhibitors, and non-steroidal topical formulations, to address unmet medical needs. Personalized medicine approaches are gaining prominence, with researchers exploring genetic and environmental factors influencing the condition. The integration of real-world evidence and digital health tools, such as wearable devices and telemedicine, is enhancing trial efficiency and patient engagement. These innovations are accelerating the development of targeted therapies for atopic dermatitis.

What Trends Are Driving Atopic Dermatitis Clinical Trials?

Several trends are shaping the atopic dermatitis clinical trials landscape. The rising prevalence of the condition, particularly in pediatric populations, has spurred research initiatives. Pharmaceutical companies are investing heavily in biologics and small-molecule drugs to capture market share in this competitive space. Patient-centric trial designs, emphasizing convenience and remote monitoring, are improving recruitment and retention rates. Additionally, regulatory incentives, such as fast-track designations for innovative treatments, are expediting trial timelines. These trends reflect the urgency to develop effective and accessible therapies for atopic dermatitis.

Why Are Biologics Dominating Atopic Dermatitis Research?

Biologics have emerged as a focal point in atopic dermatitis research due to their ability to target specific immune pathways implicated in the condition. Monoclonal antibodies, such as dupilumab, have demonstrated significant efficacy in reducing symptoms and improving quality of life for patients. The success of existing biologics has encouraged further exploration of new targets, such as IL-13 and IL-31, driving innovation in the field. These therapies offer hope for long-term disease management, especially for patients with moderate to severe forms of atopic dermatitis, reinforcing their prominence in clinical trials.

What Drives the Growth in the Atopic Dermatitis Clinical Trials Market?

The growth in the atopic dermatitis clinical trials market is driven by rising disease prevalence, advancements in biologics, and increasing adoption of patient-centric approaches. The demand for targeted therapies has encouraged pharmaceutical companies to invest in innovative treatment pipelines. Regulatory support, including orphan drug designations and expedited approvals, has incentivized clinical trial activities. Additionally, the integration of digital health technologies is streamlining trial operations and improving patient outcomes. These factors collectively underscore the significant growth potential of the atopic dermatitis clinical trials market.

SCOPE OF STUDY:

The report analyzes the Atopic Dermatitis Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Molecule Type (Small Molecules, Large Molecules); Study Design (Interventional Trials, Observational Trials); Phase (Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Phase IV Clinical Trial)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Amgen Inc.
  • Biocytogen
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • Hooke Laboratories, LLC
  • Imavita S.A.S.
  • Novartis International AG
  • Novotech
  • Oncodesign Services
  • Pfizer, Inc.
  • QIMA Life Sciences
  • Redoxis
  • Regeneron Pharmaceuticals, Inc.
  • ReproCELL, Inc.
  • Syneos Health

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP29298

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Atopic Dermatitis Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Biologic Therapies Spurs Advanced Clinical Trials
    • Growing Focus on Personalized Medicine Enhances Trial Design Complexity
    • Increasing Prevalence of Atopic Dermatitis Boosts Research Investments
    • Advancements in Genetic and Biomarker Research Drive Trial Innovation
    • Rising Pediatric Cases Lead to Specialized Trial Segments
    • Demand for Faster FDA Approvals Accelerates Adaptive Trial Designs
    • Patient-Centric Approaches Improve Trial Recruitment and Retention
    • Use of Digital Health Tools Enhances Remote Monitoring in Trials
    • Real-World Evidence Integration Expands Post-Trial Market Insights
    • Emergence of Novel Topical Therapies Broadens Clinical Pipelines
    • Artificial Intelligence Streamlines Trial Matching and Site Selection
    • Global Expansion of Trials Increases Access to Diverse Patient Populations
    • Strategic Partnerships Between Pharma and CROs Improve Trial Execution
    • Government and NGO Funding Accelerates Early-Stage Research
    • Emphasis on Long-Term Safety Data Drives Extended Trial Durations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Atopic Dermatitis Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Atopic Dermatitis Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Interventional Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Interventional Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Interventional Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Observational Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Observational Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Observational Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Phase I Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Phase I Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Phase I Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Phase II Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Phase II Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Phase II Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Phase III Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Phase III Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Phase III Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Phase IV Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Phase IV Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Phase IV Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • JAPAN
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • CHINA
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • EUROPE
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Atopic Dermatitis Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • FRANCE
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • GERMANY
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!